 |
 |
 |
 |
 |
 |
February 28, 2020
The Chordoma Foundation (CF) and The Mark Foundation for Cancer Research (MFCR) announced today a two-year, $1.4M partnership with a team of researchers at three institutions to develop new treatments for chordoma, a rare and difficult-to-treat bone cancer. The researchers will focus on creating the first drugs to inhibit a protein known as brachyury.
Photo: CHERYL ARROWSMITH AND LEVON HALABELIAN
December 2, 2019 (Toronto)
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a grant expected to total $37.5 million over five years to establish the Open-AD Drug Discovery Center. Led by Emory University, the Center includes investigators at Sage Bionetworks, Structural Genomics Consortium (SGC), Stanford University, Oxford University, and University of North Carolina.
A new type of drug that targets a genetic weakness in an untreatable childhood brain cancer could become the first ever treatment designed to target the disease.
The prototype treatment could also offer hope for patients with the rare and devastating ‘stone man syndrome’ – in which muscles and ligaments turn to bone.
Scientists at The Institute of Cancer Research, London, led research with an international team of colleagues, finding that the new drug class can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice.
This event is supported by the NIHR Oxford Biomedical Research Centre.
SGC at the University of Oxford is pleased to announce that two patient foundations, FOP Friends and FOP France, have renewed their long standing partnership with SGC Oxford to support research into the rare congenital syndrome fibrodysplasia ossificans progressiva (FOP). The research led by Dr Alex Bullock aims to better define the molecular mechanisms that cause FOP and to develop new treatments.
The focus of the Midwood lab is to develop new immuno-therapies for clinical use in treating auto-immune diseases and to re-educate anti-tumoural immunity. In 2004 Professor Midwood established the Matrix Immunology group in the Kennedy Institute at Imperial College London, moving to Oxford University in 2011. In 2007 she won an MRC New Investigators Award and in 2012 an Arthritis Research UK Senior Fellowship. She founded the BioTech company Nascient Ltd in 2012.
TORONTO (January 29, 2019) – A first-of-its-kind therapy for leukemia discovered by researchers in the Ontario Institute for Cancer Research’s (OICR) Drug Discovery Program, and under preclinical development, has attracted investment from Celgene Corporation that could exceed US$1 billion – which would make it the largest transaction to date for a preclinical asset discovered in Canada.
Highlights SGC collection of chemical probes for methyltransferases including 13 new reagents and shows how this collection may be used to discover new therapeutic uses for these probes.
Full text freely available at https://rdcu.be/bfkVw
Lysine acetylation has emerged as a key regulatory modification on histones and other proteins. Histone de-acetylaces (HDACs, the enzymes that remove lysine acetylation (Kac) from histones) are now validated drug targets in cancer, with four FDA approved drugs and several clinical trials seeking to establish higher efficacy and specificity. Kac is recognized by small protein interaction modules called bromodomains (BRDs), leading to the aggregation of complexes involved in transcription and contributing to the control of gene expression (Filippakopoulos et al., 2012; Fujisawa and Filippakopoulos, 2017).
